Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs (vol 17, pg 844, 2018)

被引：26

作者：

Charvin, Delphine

Medori, Rossella

Hauser, Robert A.

Rascol, Olivier

机构：

[1] Prexton Therapeutics, Geneva

[2] Department of Neurology, University of South Florida, Tampa, FL

[3] Centre d’Investigation Clinique CIC1436, Services de Neurologie et de Pharmacologie Clinique, Réseau NS-PARK/FCRIN et Centre COEN NeuroToul, CHU de Toulouse, INSERM, University of Toulouse 3, Toulouse

来源：

NATURE REVIEWS DRUG DISCOVERY | 2018年 / 17卷 / 11期

基金：

美国国家卫生研究院; 欧盟地平线“2020”;

关键词：

D O I：

10.1038/nrd.2018.184

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Existing therapeutic strategies for managing Parkinson disease (PD), which focus on addressing the loss of dopamine and dopaminergic function linked with degeneration of dopaminergic neurons, are limited by side effects and lack of long-term efficacy. In recent decades, research into PD pathophysiology and pharmacology has focused on understanding and tackling the neurodegenerative processes and symptomology of PD. In this Review, we discuss the challenges associated with the development of novel therapies for PD, highlighting emerging agents that aim to target cell death, as well as new targets offering a symptomatic approach to managing features and progression of the disease.

引用

页码：844 / 844

页数：1